Factors Associated With Age of Onset of Herpes Zoster Ophthalmicus. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: Chan, Annie Y.; Conrady, Christopher D.; Ding, Kai; Dvorak, Justin D.; Stone, Donald U.
• Is Part Of: Cornea. Volume 34:Issue 5(2015)
• Publication Date: 2015-05
• Subjects: varicella -- zoster -- vaccination -- smoking; Cornea -- Periodicals; Cornea -- Periodicals; Cornée -- Périodiques; 617.719
• DOI: 10.1097/ICO.0000000000000362
• Languages: English
• ISSNs: 0277-3740

Abstract

Abstract : Purpose: The aim of this study was to evaluate factors associated with the age of onset of herpes zoster ophthalmicus (HZO) in the era of varicella vaccination. Methods: A retrospective series of 400 subjects with a diagnosis of HZO, and an analysis of public health databases. Variables studied included the age at onset, period of disease onset (1996–2004 and 2005–2012), sex, smoking habits, diabetes status, autoimmunity, and immunosuppressed status. Community data were gathered from the Oklahoma Outpatient Surgery Discharge Public Use Data File and the United States Census' American Community Survey data set. Results: The mean onset age was significantly lower for 2005 to 2012 as compared with 1996 to 2004 among females (mean decrease, 9.3 years; 95% confidence interval, 4.6–13.9 years; P < 0.0001), but the mean onset age was similar between the 2 periods among males ( P = 0.640). Whereas 32.3% of the patients with zoster were <60 years old in 1996 to 2004, compared with 44.8% in the 2005 to 2012 period (χ 2 test: P = 0.017). In the multivariate model, smokers were found to have disease onset 11.5 (95% confidence interval, 6.9–16.1) years younger than nonsmokers. Conclusions: The proportion of younger patients with HZO increased, whereas the institutional and community data sets demonstrate a downward shift of the average age of onset of HZO among females. This may be an effect of widespread childhood varicella vaccination. Immunosuppression and smoking were also associated with a younger age of onset of HZO. This has implications for clinical care of patients at risk for developing HZO, as well as public health and vaccination policies.